EA202092908A1 - Модуляторы ионных каналов - Google Patents

Модуляторы ионных каналов

Info

Publication number
EA202092908A1
EA202092908A1 EA202092908A EA202092908A EA202092908A1 EA 202092908 A1 EA202092908 A1 EA 202092908A1 EA 202092908 A EA202092908 A EA 202092908A EA 202092908 A EA202092908 A EA 202092908A EA 202092908 A1 EA202092908 A1 EA 202092908A1
Authority
EA
Eurasian Patent Office
Prior art keywords
ion channel
disease
treating
condition associated
channel modulators
Prior art date
Application number
EA202092908A
Other languages
English (en)
Inventor
Эндрю Марк Гриффин
Брайан Эдвард Маррон
Габриэль МАРТИНЕС БОТЕЛЬЯ
Киран РЕДДИ
Мэрион Уитманн
Original Assignee
Праксис Пресижн Медсинз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Праксис Пресижн Медсинз, Инк. filed Critical Праксис Пресижн Медсинз, Инк.
Priority claimed from PCT/US2019/034653 external-priority patent/WO2019232209A1/en
Publication of EA202092908A1 publication Critical patent/EA202092908A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Данное изобретение относится, в частности, к конденсированным гетероарильным соединениям и композициям, применимым для предотвращения и/или лечения заболевания или состояния, связанного с аберрантной функцией потенциал-управляемого натриевого ионного канала, например, аномальным поздним/постоянным натриевым током. В данном документе также представлены способы лечения заболевания или состояния, связанного с аберрантной функцией натриевого ионного канала, включая неврологические расстройства (например, синдром Драве, эпилепсия), боль и нервно-мышечные расстройства.
EA202092908A 2018-09-28 2019-05-30 Модуляторы ионных каналов EA202092908A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862738508P 2018-09-28 2018-09-28
PCT/US2019/034653 WO2019232209A1 (en) 2018-05-30 2019-05-30 Ion channel modulators

Publications (1)

Publication Number Publication Date
EA202092908A1 true EA202092908A1 (ru) 2021-05-14

Family

ID=69949703

Family Applications (2)

Application Number Title Priority Date Filing Date
EA202092908A EA202092908A1 (ru) 2018-09-28 2019-05-30 Модуляторы ионных каналов
EA202190879A EA202190879A1 (ru) 2018-09-28 2019-09-27 Модуляторы ионных каналов

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA202190879A EA202190879A1 (ru) 2018-09-28 2019-09-27 Модуляторы ионных каналов

Country Status (12)

Country Link
US (1) US20210403476A1 (ru)
EP (1) EP3856193A4 (ru)
JP (1) JP2024019735A (ru)
KR (1) KR20210113974A (ru)
CN (1) CN113573713A (ru)
AU (1) AU2019346635A1 (ru)
BR (1) BR112021005913A2 (ru)
CA (1) CA3142470A1 (ru)
EA (2) EA202092908A1 (ru)
IL (1) IL281946A (ru)
MX (1) MX2021003634A (ru)
WO (1) WO2020069322A1 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018098491A1 (en) 2016-11-28 2018-05-31 Praxis Precision Medicines, Inc. Compounds and their methods of use
CN116763791A (zh) 2016-11-28 2023-09-19 普拉克西斯精密药物股份有限公司 化合物以及它们的使用方法
WO2018148745A1 (en) 2017-02-13 2018-08-16 Praxis Precision Medicines , Inc. Compounds and their methods of use
WO2018187480A1 (en) 2017-04-04 2018-10-11 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11278535B2 (en) 2017-08-15 2022-03-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
CN117756800A (zh) 2018-05-30 2024-03-26 普拉克西斯精密药物股份有限公司 离子通道调节剂
US11773099B2 (en) 2019-05-28 2023-10-03 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11279700B2 (en) 2019-05-31 2022-03-22 Praxis Precision Medicines, Inc. Ion channel modulators
US11505554B2 (en) 2019-05-31 2022-11-22 Praxis Precision Medicines, Inc. Substituted pyridines as ion channel modulators
US11767325B2 (en) 2019-11-26 2023-09-26 Praxis Precision Medicines, Inc. Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators
AU2022325367A1 (en) 2021-08-10 2024-02-08 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Sulfonamide derivative, preparation method therefor and medical use thereof
WO2024033374A1 (en) 2022-08-11 2024-02-15 Syngenta Crop Protection Ag Novel arylcarboxamide or arylthioamide compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4242515A (en) * 1979-03-28 1980-12-30 American Cyanamid Company Substituted 3-alkyl-6-phenyl-1,2,4-triazolo-[4,3-a]pyridines
AU2010276537B2 (en) * 2009-07-27 2015-04-16 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
WO2012065297A1 (en) * 2010-11-16 2012-05-24 Impact Therapeutics, Inc. 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
CN116763791A (zh) * 2016-11-28 2023-09-19 普拉克西斯精密药物股份有限公司 化合物以及它们的使用方法

Also Published As

Publication number Publication date
BR112021005913A2 (pt) 2021-06-29
IL281946A (en) 2021-05-31
JP2022502442A (ja) 2022-01-11
EP3856193A4 (en) 2022-08-31
CN113573713A (zh) 2021-10-29
EA202190879A1 (ru) 2021-08-16
US20210403476A1 (en) 2021-12-30
WO2020069322A1 (en) 2020-04-02
AU2019346635A1 (en) 2021-05-20
MX2021003634A (es) 2021-07-16
KR20210113974A (ko) 2021-09-17
CA3142470A1 (en) 2020-04-02
JP2024019735A (ja) 2024-02-09
EP3856193A1 (en) 2021-08-04

Similar Documents

Publication Publication Date Title
EA202190879A1 (ru) Модуляторы ионных каналов
MX2024000150A (es) Moduladores de los canales ionicos.
SA522432719B1 (ar) مُنظِمات قناة أيونية
EP4397308A3 (en) Compounds and their methods ofuse
MX2022006452A (es) Formulaciones de moduladores de canales ionicos y metodos de preparacion y uso de moduladores de canales ionicos.
EA201991142A1 (ru) Варианты il-2 для лечения аутоиммунных заболеваний
PH12018502258A1 (en) Isoquinolin-3-yl carboxamides and preparation and use thereof
EA201991553A1 (ru) (аза)индол-, бензотиофен- и бензофуран-3-сульфонамиды
EA201990187A1 (ru) Антипролиферационные средства на основе пиримидина
PH12018501288A1 (en) Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels
EA201591746A1 (ru) Способы и композиции для ингибирования бромодомен-содержащих белков
EA202092086A1 (ru) Ингибиторы аргиназы
PH12020552092A1 (en) Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease
RU2018115781A (ru) Условно активные полипептиды
PH12017502123A1 (en) Substituted benzamides and methods of use thereof
EA202090414A1 (ru) Соединения и их применение
EA201891469A1 (ru) Агонист длительного действия glp-1r как терапия для лечения неврологических и нейродегенеративных патологических состояний
EA202091428A1 (ru) Замещенные амиды ii пирролидина
EA201590379A1 (ru) Пирролопиразолы, используемые в качестве блокаторов кальциевых каналов n-типа
MX2020005545A (es) Compuestos para el tratamiento de trastornos neuromusculares.
PH12020552172A1 (en) Cyclic dinucleotides as sting agonists
EA201890460A1 (ru) Композиции и способы лечения и предотвращения нейродегенеративных расстройств
AU2020264106A8 (en) Small molecule bromodomain inhibitors and uses thereof
EA202091429A1 (ru) Замещенные амиды i пирролидина
EA201991128A1 (ru) ТРИЦИКЛИЧЕСКИЕ СУЛЬФОНЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORγ